This paper focuses on one such example of race adjustment, hypertension management guidelines, which commonly assert that angiotensin-converting enzyme (ACE) inhibitors are not as efficacious and should not be prescribed as initial antihypertensive therapy for Black patients.2,3 The urgency around this dilemma has intensified as emerging data demonstrates that even when racialized hypertension treatment guidelines are widely used, they do not appear to reduce racial disparities in hypertension control.4 This evidence concerns the gene ACE and hypertensive disorder.